Recent Publications by QLT: |
Photodynamic therapy in immune (non-oncological) disorders: focus on benzoporphyrin derivatives.
This review examines the efficacy of photodynamic therapy in the treatment... | 24th November, 2007
| QLT Inc., Vancouver, British Columbia, Canada.
| BioDrugs. 2000 Aug;14(2):127-35.
|
Ultraviolet B light stimulates interleukin-20 expression by human epithelial keratinocytes.
The proinflammatory cytokine interleukin-20 (IL-20) may exert the majority... | 1st June, 2007
| Scientific Affairs: Dermatology, QLT, Inc., Vancouver, British Columbia,
| Photochem Photobiol. 2006 Sep-Oct;82(5):1292-300.
DOI Direct Link |
Lack of effect of sex and disease state on the pharmacokinetics of porfimer sodium.
BACKGROUND: Porfimer sodium is an agent used for photodynamic therapy... | 12th May, 2007
| QLT Inc, Vancouver, British Columbia, Canada.
| Clin Pharmacokinet. 2006;45(9):923-30.
|
Influence of interleukin-1alpha on androgen receptor expression and cytokine secretion by cultured human dermal papilla cells.
Dermal papilla cells (DPC) control the growth character of the hair... | 12th December, 2006
| Scientific Affairs: Dermatology, QLT Inc., 887 Great Northern Way,
| Exp Dermatol. 2006 Oct;15(10):784-93.
DOI Direct Link |
Cellular and antitumor activity of a new diethylene glycol benzoporphyrin derivative (lemuteporfin).
A newly synthesized diethylene glycol functionalized chlorin-type... | 14th June, 2006
| QLT Inc., 887 Great Northern Way, Vancouver, BC, Canada, V5T 4T5.
| Photochem Photobiol. 2006 Jan-Feb;82(1):219-24.
DOI Direct Link |
Rapid induction of apoptosis in human keratinocytes with the photosensitizer QLT0074 via a direct mitochondrial action.
QLT0074 is a newly introduced, porphyrin-derivative for use in... | 15th April, 2004
| Department of Preclinical Pharmacology, QLT Inc., 887 Great Northern Way,
| Apoptosis. 2003 Jun;8(3):269-75.
|
Status of therapies in development for the treatment of age-related macular degeneration.
Age-related macular degeneration (AMD) is among the leading causes of... | 5th September, 2003
| QLT Inc, Preclinical Development, 887 Great Northern Way, Vancouver BC,
| IDrugs. 2003 May;6(5):464-9.
|
Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin.
BACKGROUND: Verteporfin (Visudyne, Novartis AG) is a light-activated drug... | 4th February, 2003
| QLT Inc., 887 Great Northern Way, Vancouver, British Columbia V5T 4T5,
| Retina. 2002 Dec;22(6):691-7.
|
Clinical pharmacokinetics of verteporfin.
Verteporfin, a benzoporphyrin derivative, is the first photo-sensitive... | 20th December, 2002
| QLT Inc., Vancouver, BC, Canada.
| J Clin Pharmacol. 2002 May;42(5):547-57.
|
Selective action of the photosensitizer QLT0074 on activated human T lymphocytes.
A new photosensitizer, presently designated QLT0074, may have the... | 9th October, 2002
| QLT Inc., 887 Great Northern Way, Vancouver, British Columbia, Canada.
| Photochem Photobiol. 2002 Aug;76(2):224-31.
|
